The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
The Bidar API manufacturing facility of Sai Life Sciences has been on a path of significant expansion with its production capacity growing from 200KL in 2017 to 450KL
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
The lab has been developed to aid surgeons to overcome the challenging learning curve to obtain laparoscopic expertise
A sum of Rs 70 crores and Rs 10 crores for a new Ayurvedic college in Assam and upgradation of the ayurvedic college in Guwahati respectively
The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India
In the last two years, Sai Life Sciences has made significant investments and progress in advancing its sustainability agenda as part of its organizational transformation initiative
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
Subscribe To Our Newsletter & Stay Updated
